Table 4.

Univariate and multivariate Cox regression for BOS. Shown in (A) are the various transformations of BALF biomarkers utilized in the model. In the adjusted models for CXCL9 and CXCL10 (B and C), variables were included if they changed the model by >10% in addition to the last biomarker measure. Shown are the HR for developing BOS with the 95% confidence intervals

Univariate biomarker transformation	Hazard ratio (95% CI)	p-Value
(A) Unadjusted model
CXCL9 last reading	1.11 (1.04–1.19)	<0.01
CXCL9 mean	2.03 (1.28–3.24)	<0.01
CXCL9 AUC	1.9 (1.2–3.01)	0.01
CXCL9 sum	1.92 (1.25–2.96)	<0.01
CXCL9 maximum	1 (0.99–1.01)	0.62
CXCL10 last reading	3.8 (2.09–6.91)	<0.01
CXCL10 mean	2.24 (1.35–3.7)	<0.01
CXCL10 AUC	2.84(1.67–4.85)	<0.01
CXCL10 sum	2.2 (1.33–3.65)	<0.01
CXCL10 maximum	1 (0.99–1.01)	0.58

CXCL9 parameter	Crude hazard ratio (95% CI)	Hazard ratio adjusted for last measure (95% CI)	Hazard ratio adjusted for diagnosis (95% CI)
(B) Adjusted CXCL9 model
CXCL9 AUC	1.9 (1.2–3.08)	1.78 (1.12–2.85)	2.18 (1.31–3.65)
CXCL9 last measure		1.04 (0.95– 1.13)
Diagnosis (Obstructive vs. Restrictive)			0.33 (0.1–1.16)

CXCL10 Parameter	Crude Hazard Ratio (95% CI)	Hazard ratio adjusted for last measure (95% CI)	Hazard ratio adjusted for gender (95% CI)	Hazard ratio adjusted for donor age (95% CI)	Hazard ratio adjusted for diagnosis (95% CI)
(C) Adjusted CXCL10 Model
CXCL10 AUC	2.84(1.67–4.85)	1.92(0.97–3.80)	3.32 (1.75–6.3)	3.82 (1.89–7.78)	4.00 (2.04–7.85)
CXCL10 last measure		2.98 (1.55–5.75)
Gender (Female)			0.54 (0.17– 1.67)
Donor age				0.96 (0.92–1.01)
Diagnosis (obstructive vs. restrictive)					0.25 (0.07–0.97)